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#NM46 | EVALUATION OF MOBILE
HEALTH APPLICATIONS FOR PELVIC
ORGAN PROLAPSE AND STRESS
URINARY INCONTINENCE
Moli Karsalia, BS, Rena Malik, MD
University of Maryland School of Medicine

Presented By: Moli Karsalia
Introduction: As technology becomes integrated into
healthcare, it becomes important to evaluate mobile
health applications (apps). We aim to evaluate apps for
Pelvic Organ Prolapse and Stress Urinary Incontinence
using Xcertia guidelines for medical app quality and
analyze app usage.
Methods: Mobile medical apps were found on the
Apple App Store or Google Play Store with keywords
“pelvic organ prolapse,” “incontinence,” or “bladder.”
Exclusion criteria included 1) not free, 2) not updated in
past year, 3) required a product for use, 4) not in English.
Apps were evaluated along the Xcertia Guidelines. Categories included Operability, Privacy, Security, Content,
and Usability. Ratings and sentiment of reviews were
assessed.
Results: On the Apple Store, 27 apps were found and
7 were included. There was an average of 143.6 ratings,
with an average score of 4.56. Review sentiment analysis
showed 4 apps with majority positive sentiment, 1 with
mostly negative reviews, 1 with mostly neutral reviews,
and 1 had equal positive, negative, and neutral reviews.
On the Google Play Store, 46 apps were found and 21
were included. There was an average of 2968.8 ratings,
with an average score of 4.21. Review sentiment showed
11 apps with majority positive sentiment, 3 with majority
negative, 0 with majority neutral, and 7 with equal
reviews.
Based on Xcertia Guidelines, all apps met the
guidelines for privacy, security, and usability. Regarding
content, 57.1% of Apple apps incorporated an informational component and 28.5% delineated sources, while
71.4% of Google Play apps had an informational component, but only 14.3% provided their sources. For operability, 57.1% of Apple apps had developer contact
information available, while all of the Google Play
apps did.
Conclusion: Most apps were functional and well received by users, however quality of app content varied.
Only some apps had an informational component, and
even less had sources listed. Providers recommending
health apps should consider those that meet Xcertia
guidelines and have reliable information.
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Introduction: Previous studies have shown that the
fractional carbon dioxide (fCO2) vaginal laser improves
genitourinary symptoms of menopause. It has been
proposed that fCO2 vaginal laser can also treat stress
urinary incontinence (SUI) by increasing collagen production. The aim of our study was to evaluate the effect
of vaginal fCO2 laser therapy in patient complaining
of SUI.
Methods: Women over 18 years old with complaints
of urogenital symptoms who had been off vaginal estrogen for at least three months were enrolled in this open‐
label prospective trial. Participants received 3 laser
treatments approximately 6 weeks apart. Stress test was
performed on patients at each visit. Responses to the
Incontinence‐Quality of Life (I‐QOL), Questionnaire for
Urinary Incontinence Diagnosis (QUID), and Female
Sexual Function Index (FSFI) were collected at each
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treatment visit and at 6‐month follow‐up. Responses to
the Patient Global Impression of Improvement (PGI‐I)
were collected after the first treatment and then at every
follow‐up visit. ANOVA analysis was used to compare
means at each time point.
Results: A total of 58 participants were enrolled. Of
these, 75.9% (44/58) complained of SUI. Analysis was
performed on the total of 30 participants who had undergone three treatments. Sixty‐three percent (19/30)
were post‐menopausal. Mean follow‐up time was 7.7 (SD
3.7) months. Baseline stress test was positive in 6 of the
30 patients (20%). Stress test data was available for 12
patients at the 6‐month follow‐up and was positive in 2
patients (16.7%). No difference was seen in total FSFI, I‐
QOL, or the QUID‐stress sub‐score at the 6‐month visit.
There was a trend towards improvement in the QUID‐
urge sub‐score and the QUID‐total (p = 0.06). The mean
PGI‐I scores showed increased improvement after each
treatment and at 6‐months (p<0.01), Table 1.
Conclusion: Our preliminary results of this open‐
label fCO2 vaginal laser show no objective or subjective
improvement in SUI after three treatments. Sexual
function symptoms also did not significantly decrease
after three treatments. However, there was a trend towards improvement in urge symptoms and patients did
report global improvement after each treatment. Further
data with larger numbers and longer follow‐up are needed to confirm these early findings.

Funding: The Cooper Fund

#NM48 | THE ROLE OF PESSARIES IN
THE TREATMENT OF WOMEN WITH
STRESS URINARY INCONTINENCE: A
SYSTEMATIC REVIEW
Julia Klein1, Michelina Stoddard, PhD2, Bills
Chughtai, MD2
1

Weill Cornell Medicine, 2Department of Urology, Weill Medical College
of Cornell University

ABSTRACTS

Presented By: Julia Klein, BA
Introduction: Pessaries have recently resurfaced as a
viable non‐surgical treatment option in recent years in
light of complications associated with mesh used in the
surgical treatment of SUI. While the efficacy of pessaries
in SUI has been studied, few high‐quality studies with
large cohorts exist. The purpose of this systematic review
and meta‐analysis is to synthesize existing evidence to
determine the sort‐term efficacy of pessaries for SUI
using patient reported outcomes (PROs) and objective
measures.
Methods: This review was approved by the PROSPERO database (CRD42020191677). PubMed, EMBASE
and CINAHL were searched using the MeSH terms
“stress urinary incontinence” and “pessary, pessaries
or pessarium”. Studies were either randomized control
trials, prospective cohort studies, prospective observational studies, retrospective cohort studies that included PROs or objective urodynamic data. Studies on
pregnant women, pediatric populations, women using
pessaries for indications other than SUI, and women
using electronic pessaries were excluded. The search
yielded 612 unique articles, of which 14 studies were
included in the analysis. Primary outcomes were PROs,
such as feeling continent, the Urogenital Distress Inventory (UDI), and the Incontinent Impact Questionnaire (IIQ). Secondary outcomes included
objective measures such as the pad test, post‐void residual (PVR), urethral closure pressure, and pessary
continuation rates.
Results: Participants were aged 51.4±4.1yr (n = 915,
mean±SD) and primarily Caucasian (67%). At baseline,
parity was 2.1±0.5 (n=615), 46.36% were postmenopausal (n=732), 8.04% had undergone prior UI
surgery was (n=734), and 25.34% had undergone prior
nonsurgical UI treatment (n=592). After pessary treatment, 76% of women reported feeling continent (compared to 0% at baseline, n=154 at follow‐up, p<0.0001).
Furthermore, UDI scores decreased by 44.3% (n=160,
p<0.0001), and IIQ scores decreased by 65.3% (n=118, p
< 0.0001). At 1.5‐6 months follow‐up, 78% of women
continued to use the pessary (n=124, p<0.0001), pad
weight decreased by 57.6% (n=68, p<0.0001), and urethral closure pressure increased by 33.8% (n=122,
p<0.0001). PVR increased by 15.1%, although not significantly (n=125, p=0.0550).
Conclusion: Pessaries offer an effective alternative
for patients who desire conservative treatment of SUI.
This systematic review and meta‐analysis demonstrates
that pessaries are effective in the non‐surgical treatment
of SUI.
Funding: N/A

